Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China
Wenting Zuo, Di He, Chaoyang Liang, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 8, pp. 845-855
Open Access | Times Cited: 57
Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report
Neta S. Zuckerman, Efrat Bucris, Danielle Keidar-Friedman, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 2, pp. 352-355
Closed Access | Times Cited: 53
The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
Andrea Antinori, Mary T. Bausch-Jurken
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S4-S12
Open Access | Times Cited: 43
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages
Harold Marcotte, Yunlong Cao, Fanglei Zuo, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 3
Open Access | Times Cited: 18
Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study
Sung‐Woon Kang, Jun-Won Kim, Ji Yeun Kim, et al.
Journal of Infection (2023) Vol. 86, Iss. 4, pp. 412-414
Open Access | Times Cited: 29
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
Xuan Wang, Katrin Haeussler, Anne Spellman, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection
Zeno Pasquini, Alice Toschi, Beatrice Casadei, et al.
Hematological Oncology (2023) Vol. 41, Iss. 5, pp. 904-911
Open Access | Times Cited: 22
B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience
Alessandra D’Abramo, Serena Vita, Alessia Beccacece, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 10
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 10
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 7, pp. 1419-1438
Open Access | Times Cited: 6
How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic
Michael Boeckh, Steven A. Pergam, Ajit P. Limaye, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 5
Predicting persistent SARS-CoV-2 shedding in immunocompromised patients: a probability-based approach
Euijin Chang, Jun-Won Kim, Choi‐Young Jang, et al.
Infectious Diseases (2025), pp. 1-10
Closed Access
COVID‐19 in pregnancy
Orene Greer, Zainab Saeed, Ee Von Woon, et al.
The Obstetrician & Gynaecologist (2025) Vol. 27, Iss. 1, pp. 43-56
Open Access
The impact of remdesivir on SARS-CoV-2 evolution in vivo
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, et al.
JCI Insight (2025)
Open Access
Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma
Kou Kimoto, Hitoshi Kawasuji, Yoshihiro Yoshida, et al.
Cureus (2025)
Open Access
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, et al.
EBioMedicine (2025) Vol. 113, pp. 105613-105613
Open Access
Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
Felipe Lopes de Assis, Kenneth B. Hoehn, Xiaozhen Zhang, et al.
Cell Reports (2023) Vol. 42, Iss. 7, pp. 112780-112780
Open Access | Times Cited: 14
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Ivan Gentile, Maria Foggia, Maria Silvitelli, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy
María Stefania Infante, David Nemirovsky, Sean M. Devlin, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 116.e1-116.e12
Open Access | Times Cited: 12
CD4 + and CD8 + T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
Meenakshi Kar, Katherine Johnson, Abigail Vanderheiden, et al.
Science Advances (2024) Vol. 10, Iss. 34
Open Access | Times Cited: 4
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
Tal Brosh‐Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 57, Iss. 1, pp. 189-194
Open Access | Times Cited: 10
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top